Il y a eu 50 transactions d'initiés récentes enregistrées pour Arbutus Biopharma Corporation (ABUS), dont 31 achats et 10 ventes. Le total des achats d'initiés s'élève à $16.12M et le total des ventes d'initiés à $528.88K.
Les initiés notables ayant une activité récente comprennent Androski Lindsay, Nguyen Tuan, Sawhney Roger. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — ABUS
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-02-02 |
Androski Lindsay |
President and CEO |
Attribution de RSU |
28,000 |
- |
- |
28,000 |
| 2026-02-02 |
Nguyen Tuan |
Chief Financial Officer |
Attribution de RSU |
73,500 |
- |
- |
73,500 |
| 2025-08-04 |
Sawhney Roger |
Director |
Inconnu |
- |
- |
- |
- |
| 2025-08-04 |
Sawhney Roger |
Director |
Attribution de RSU |
157,600 |
$3.34 |
$526.38K |
157,600 |
| 2025-03-31 |
Nguyen Tuan |
Chief Financial Officer |
Attribution de RSU |
750,000 |
$3.50 |
$2.63M |
750,000 |
| 2025-03-31 |
Nguyen Tuan |
Chief Financial Officer |
Attribution de RSU |
750,000 |
$3.49 |
$2.62M |
750,000 |
| 2025-03-28 |
Nguyen Tuan |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-03-18 |
Beardsley Robert A |
Director |
Attribution de RSU |
157,600 |
$3.20 |
$504.32K |
157,600 |
| 2025-03-18 |
Androski Lindsay |
President and CEO |
Attribution de RSU |
310,422 |
$3.20 |
$993.35K |
310,422 |
| 2025-03-18 |
Hasija Anuj |
Director |
Attribution de RSU |
157,600 |
$3.20 |
$504.32K |
157,600 |
| 2025-02-24 |
Beardsley Robert A |
Director |
Inconnu |
- |
- |
- |
- |
| 2025-02-24 |
Gline Matthew |
10 Percent Owner |
Inconnu |
- |
- |
- |
38,847,462 |
| 2025-02-24 |
Androski Lindsay |
President and CEO |
Inconnu |
- |
- |
- |
- |
| 2025-02-24 |
Hasija Anuj |
Director |
Inconnu |
- |
- |
- |
- |
| 2025-02-24 |
Bishop Joseph E |
Director |
Inconnu |
- |
- |
- |
- |
| 2025-02-14 |
Hastings David C |
Chief Financial Officer |
Attribution de RSU |
90,100 |
- |
- |
249,824 |
| 2025-02-14 |
Naftzger J. Christopher |
General Counsel and Cco |
Attribution de RSU |
54,300 |
- |
- |
140,544 |
| 2025-02-14 |
Mcelhaugh Michael J. |
Interim President & CEO |
Attribution de RSU |
718,800 |
$3.29 |
$2.36M |
718,800 |
| 2025-02-14 |
Sims Karen |
Chief Medical Officer |
Attribution de RSU |
49,300 |
- |
- |
155,494 |
| 2025-02-04 |
Hastings David C |
Chief Financial Officer |
Vente Informative |
22,183 |
$3.28 |
$72.83K |
159,724 |
| 2025-02-04 |
Naftzger J. Christopher |
General Counsel and Cco |
Vente Informative |
11,333 |
$3.28 |
$37.21K |
86,244 |
| 2025-02-04 |
Mcelhaugh Michael J. |
Interim President & CEO |
Vente Informative |
23,790 |
$3.28 |
$78.1K |
1,481,003 |
| 2025-02-04 |
Sims Karen |
Chief Medical Officer |
Vente Informative |
19,348 |
$3.28 |
$63.52K |
106,194 |
| 2024-08-14 |
Manchester Keith S |
Director |
Exercice d'Options (Vente) |
54,915 |
$0.56 |
$30.75K |
- |
| 2024-05-23 |
Henriques Richard C Jr |
Director |
Attribution de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Burgess Daniel D |
Director |
Attribution de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Manchester Keith S |
Director |
Attribution de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Meyers James R |
Director |
Attribution de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Torti Frank |
Director |
Attribution de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Rewolinski Melissa |
Director |
Attribution de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-02-02 |
Hastings David C |
Chief Financial Officer |
Vente Informative |
9,593 |
$2.31 |
$22.18K |
181,907 |
| 2024-02-02 |
Sofia Michael J. |
Chief Scientific Officer |
Vente Informative |
9,982 |
$2.31 |
$23.08K |
1,485,121 |
| 2024-02-02 |
Mcelhaugh Michael J. |
Interim President & CEO |
Vente Informative |
10,164 |
$2.31 |
$23.5K |
1,504,793 |
| 2024-02-02 |
Sims Karen |
Chief Medical Officer |
Vente Informative |
4,358 |
$2.31 |
$10.08K |
125,542 |
| 2024-02-01 |
Hastings David C |
Chief Financial Officer |
Attribution de RSU |
112,500 |
- |
- |
191,500 |
| 2024-02-01 |
Naftzger J. Christopher |
General Counsel and Cco |
Attribution de RSU |
95,100 |
- |
- |
95,100 |
| 2024-02-01 |
Sofia Michael J. |
Chief Scientific Officer |
Attribution de RSU |
437,800 |
$2.40 |
$1.05M |
437,800 |
| 2024-02-01 |
Mcelhaugh Michael J. |
Interim President & CEO |
Attribution de RSU |
495,100 |
$2.40 |
$1.19M |
495,100 |
| 2024-02-01 |
Sims Karen |
Chief Medical Officer |
Attribution de RSU |
101,000 |
- |
- |
129,900 |
| 2023-07-12 |
Rewolinski Melissa |
Director |
Inconnu |
- |
- |
- |
- |
| 2023-07-12 |
Rewolinski Melissa |
Director |
Attribution de RSU |
110,000 |
$2.27 |
$249.7K |
110,000 |
| 2023-07-10 |
Naftzger J. Christopher |
Officer |
Inconnu |
- |
- |
- |
- |
| 2023-07-10 |
Naftzger J. Christopher |
General Counsel and Cco |
Attribution de RSU |
500,000 |
$2.26 |
$1.13M |
500,000 |
| 2023-07-10 |
Sims Karen |
Chief Medical Officer |
Cession |
57,800 |
$2.90 |
$167.62K |
- |
| 2023-07-10 |
Sims Karen |
Chief Medical Officer |
Attribution de RSU |
153,640 |
$2.26 |
$347.23K |
153,640 |
| 2023-05-24 |
Henriques Richard C Jr |
Director |
Attribution de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Burgess Daniel D |
Director |
Attribution de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Manchester Keith S |
Director |
Attribution de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Meyers James R |
Director |
Attribution de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Torti Frank |
Director |
Attribution de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
